Cancer Treatment Complexity And Costs Increased Substantially Over Two Decades
Executive Summary
A QuintilesIMS Institute study of global oncology trends illustrates the benefits and downside of therapeutic advances – more therapeutic options with better targeting, but also significantly higher complexity in setting a therapeutic course, which is complicated by rising costs.
You may also be interested in...
NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate
Authors propose imposing penalties on drugmakers who don't start confirmatory trials shortly after accelerated approval and additional discounts for public payers; proposals could pick up steam among congressional democrats amid their renewed call for lower drug prices.
Immuno-Oncology 2.0 Roundtable: Scientific And Pricing Challenges Can't Slow New Therapies
Scrip spoke with executives from five companies about challenges that remain for the burgeoning – but still young – immuno-oncology field in Part 2 of a wide-ranging roundtable discussion.
Concerned About Unsustainable Cancer Drug Prices? Here's An Idea
A group of leading researchers are suggesting that using academic centers to de-risk cancer drug discovery could tackle the problem of 'unsustainable drug prices'.